and steroid-resistant severe acute GVHD, successfully controlled with FK506. We report our findings in two cases of steroid-resistant severe acute GVHD after allogeneic BMT successfully treated with FK506 (tacrolimus). An 18-year-old female Case reports (patient 1) who underwent BMT from an HLA-identical sibling for ALL in first CR, developed generalized eryPatient 1 thema and profuse watery diarrhea, which progressed
half of the starting dose, blood levels of FK506 remained FK506 (tacrolimus), a new potent immunosuppressant, as high as 27-38 ng/ml, and then the dose was reduced to has been reported to be effective for prevention of solid-0.0375 mg/kg resulting in lower levels of 22-28 ng/ml. At organ graft rejection. 5 Since not much is known about its the end of the treatment period, the drug dose was tapered efficacy in the treatment of GVHD after allogeneic BMT, without relapse of GVHD. we investigated its clinical application for this purpose. In the present report, we describe two patients with CYA-, Patient 2
A 9-year-old girl was first diagnosed as having AML (FAB after consolidation therapy. During first remission, an unreIn contrast, both of the patients reported here demonstrated a persistent response to FK506 used for steroidlated male donor was allocated by the Japanese Bone Marrow Donor Registry. The HLA types of the patient and resistant severe acute GVHD after allogeneic BMT. The patients remain alive without any sequelae or any signs of donor were phenotypically identical: A2, A24(10), B13, B51(5), DRB1 * 1202, DRB1 * 0901. Retrospective DNA chronic GVHD more than a year later. One possible reason for our successful treatment was that FK506 was adminisanalysis of HLA revealed mismatches in A, DPA1, and DPB1 loci: A0201, 2402 (patient) vs A0206, 2402 (donor), tered by 24-h intravenous infusion, maintaining plasma concentrations between 25 and 35 ng/ml during the pro-DPA1 * 02022, 0201 (patient) vs DPA1 * 02022 (donor), and DPB1 * 1401, 0501 (patient) vs DPB1 * 0201, 0501 (donor).
gressive phase of acute GVHD, without severe adverse effects. Continuous infusion of FK506 has the advantage The ABO blood types of the patient (O rhesus positive) and the donor (A rhesus positive) were also different. After of allowing rapid dose adjustment at the first sign of drug toxicity, and avoiding the toxic peak plasma concentration conditioning with CY (60 mg/kg/day) for 2 days followed by fractionated TBI (2 Gy × 6), she received 3.2 × 10 8 /kg of (nearly three times higher than that reached during continuous infusion) observed soon after completion of a bolus erythrocyte-depleted bone marrow cells from the unrelated donor in September 1994. GVHD prophylaxis consisted of infusion. 9 Hypertrophic cardiomyopathy has been reported in pediatric transplant patients treated with FK506 at trough CYA (3 mg/kg/day, in two divided doses) and MTX on days 1 (15 mg/m 2 ), 3, 6 and 11 (10 mg/m 2 ). After concentrations between 20 and 40 ng/ml for over a month.
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Transient chest pain without any abnormal electrocardioengraftment, facial exanthema occurred on day 13, which then spread over her entire body (Figure 2 ). Although graphic findings was observed in patient 2. However, none of the adverse effects were sufficiently serious to require prednisolone was given at 2 mg/kg, the skin lesions developed into generalized erythrodermia, followed by processation of treatment.
In conclusion, to control steroid-resistant severe acute fuse watery diarrhea (more than 1500 ml/day) with abdominal pain severe enough to require morphine for its allevi-GVHD, it seems to be important to give FK506 at plasma concentrations as high as 25-35 ng/ml over 24 h for long ation. Serum bilirubin levels rose to 9.7 mg/dl (Figure 2) . The clinical features were in accordance with stage IV periods by continuous intravenous infusion. Careful monitoring of clinical findings, including cardiac function, is GVHD and high-dose methylprednisolone (1000 mg/m 2 ) was given. This proved effective for the skin lesions, but indicated during the therapy. not for the gut and liver involvement. CYA was discontinued and FK506 in combination with prednisolone was administered by continuous intravenous infusion, keeping References blood levels between 25 and 35 ng/ml for a month, and
